Premier Alternatives

Ancilia Bio

Drug Discovery · New York, NY · Founded 2019 · Privately Held (backing)

Developer of virus-resistant live bacterial products designed to modulate the human microbiome. Ancilia Bio is based in New York, NY and was founded in 2019. It was valued at $28 million at its seed round in Apr 2026, the last priced event on record. It has raised $11.1 million across 1 recorded round; the latest was an early-stage round in Apr 2023.

PMV mark · valuation
$28.0M
Oct 2026
Priced at
its seed round
Apr 2026
Total raised
$11.1M
Last round
Early Stage VC
Apr 2023
How much has Ancilia Bio raised?
$11.1Macross 1 recorded rounds · Apr 2023 – Apr 2023

Most recently, Ancilia Bio raised an undisclosed amount in its Early Stage VC (Apr 2023).

Free account
More of Ancilia Bio with a free account
  • ·The complete investor list: 13 names
  • ·Watch Ancilia Bio: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Ancilia Bio round by round

1 rounds
Apr 2023Early Stage VCundisclosed▮
+ 1 more investors · free account

How much has Ancilia Bio raised?

Ancilia Bio has raised $11.1 million in total; 1 of its rounds is on record. The most recent was an early-stage round in Apr 2023.

Ancilia Bio investors

13 investors are on record for Ancilia Bio, including US National Science Foundation, Metaplanet Holdings, National Institutes of Health and New York Ventures. By type, the record holds 5 venture capital firms. The early-stage round in Apr 2023 drew 2 investors.

For fundraisers
Raising for a company like Ancilia Bio?

13 investors have backed Ancilia Bio — start your target list with the firms already writing checks in drug discovery.

See all 13 investors →

Frequently asked about Ancilia Bio

How much has Ancilia Bio raised?
Ancilia Bio has raised $11.1M in total across 1 recorded funding rounds.
When was Ancilia Bio's last funding round?
Ancilia Bio's most recent recorded round was Early Stage VC in Apr 2023.